BR112018001053A2 - compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo - Google Patents

compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo

Info

Publication number
BR112018001053A2
BR112018001053A2 BR112018001053A BR112018001053A BR112018001053A2 BR 112018001053 A2 BR112018001053 A2 BR 112018001053A2 BR 112018001053 A BR112018001053 A BR 112018001053A BR 112018001053 A BR112018001053 A BR 112018001053A BR 112018001053 A2 BR112018001053 A2 BR 112018001053A2
Authority
BR
Brazil
Prior art keywords
compounds
inhibiting
preventing
individual
pharmaceutical composition
Prior art date
Application number
BR112018001053A
Other languages
English (en)
Inventor
Chen Chun-Han
Liou Jing-Ping
Yen Yun
Original Assignee
Univ Taipei Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Taipei Medical filed Critical Univ Taipei Medical
Publication of BR112018001053A2 publication Critical patent/BR112018001053A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings

Abstract

a invenção fornece uma série de compostos de azaarila substituídos com clorobenzeno tendo atividade na inibição do crescimento de células cancerosas e baixa toxicidade em células normais. particularmente, os compostos da invenção têm um efeito de inibição mais forte no câncer de bexiga e no câncer de fígado.
BR112018001053A 2015-07-20 2016-07-20 compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo BR112018001053A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562194705P 2015-07-20 2015-07-20
PCT/US2016/043203 WO2017015400A1 (en) 2015-07-20 2016-07-20 Chlorobenzene substituted azaaryl compounds

Publications (1)

Publication Number Publication Date
BR112018001053A2 true BR112018001053A2 (pt) 2018-09-11

Family

ID=57834598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001053A BR112018001053A2 (pt) 2015-07-20 2016-07-20 compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo

Country Status (9)

Country Link
US (1) US10624897B2 (pt)
EP (1) EP3324970A4 (pt)
JP (1) JP2018527321A (pt)
CN (1) CN108348519A (pt)
AU (1) AU2016296997B2 (pt)
BR (1) BR112018001053A2 (pt)
CA (1) CA2993022A1 (pt)
TW (1) TWI694067B (pt)
WO (1) WO2017015400A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110283130B (zh) * 2019-07-05 2023-12-19 温州医科大学 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用
CN114450277A (zh) * 2019-09-30 2022-05-06 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的经取代的嘧啶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
MX354783B (es) * 2012-03-30 2018-03-21 Novartis Ag Inhibidor de fgfr para su uso en el tratamiento de trastornos hipofosfatemicos.
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors

Also Published As

Publication number Publication date
TWI694067B (zh) 2020-05-21
CA2993022A1 (en) 2017-01-26
WO2017015400A1 (en) 2017-01-26
EP3324970A4 (en) 2019-03-06
US10624897B2 (en) 2020-04-21
EP3324970A1 (en) 2018-05-30
AU2016296997B2 (en) 2020-07-09
CN108348519A (zh) 2018-07-31
JP2018527321A (ja) 2018-09-20
TW201720800A (zh) 2017-06-16
AU2016296997A1 (en) 2018-03-08
US20190083499A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
BR112018008877A2 (pt) inibidores de ret
BR112018073329A2 (pt) combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
BR112018004620A2 (pt) moduladores da expressão de kras
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018016968A2 (pt) derivados de carboxamida úteis como inibidores de rsk
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
BR112017023225A2 (pt) inibidor de proteína cinase
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112017018198A2 (pt) inibição da atividade de olig2
CO2020015377A2 (es) Moduladores de la expresión de apol1
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
UY38352A (es) Inhibidores de integrina alfavbeta6
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
BR112018072664A2 (pt) composições e métodos para tratamento de inflamação e infecção do olho
BR112018001053A2 (pt) compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements